Acute cholangitis is diagnosed on the basis of the clinical features, supported by laboratory evidence of systemic infection. Imaging is helpful in revealing biliary obstruction and any underlying ...

PARIS — Statins can significantly reduce the risk for complications and death from primary sclerosing cholangitis, results from a Swedish registry study show. Primary sclerosing cholangitis is ...

Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits. In this phase 3, ...

The survey of European hepatologists demonstrates the lack of clarity in guidelines. A new survey of European health care centers with expertise in managing primary sclerosing cholangitis (PSC) ...

Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an ...

Primary sclerosing cholangitis (PSC) is a chronic autoimmune disease with inflammation and stricture formation in the bile ducts inside the liver and/or in the extrahepatic bile duct which drains into ...

EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

Please provide your email address to receive an email when new articles are posted on . In line with an earlier panel decision, FDA denied full approval to Ocaliva for primary biliary cholangitis. FDA ...